ID Source | ID |
---|---|
PubMed CID | 637930 |
CHEMBL ID | 1451833 |
MeSH ID | M0160745 |
Synonym |
---|
fumarsaeuredinitril |
fumaronitrile |
764-42-1 |
nsc-17555 |
fumaric nitrile |
2-butenedinitrile, (e)- |
fumarodinitrile |
nsc17555 |
furmaronitrile |
trans-1,2-dicyanoethylene |
2-butenedinitrile, (2e)- |
(2e)-but-2-enedinitrile |
NCGC00091246-01 |
ccris 1629 |
fumaric acid dinitrile |
trans-1,2-dicyanoethene |
nsc 17555 |
fumarsaeuredinitril [german] |
einecs 212-122-3 |
(e)-1,2-dicyanoethylene |
fumaronitrile, 98% |
smr001370901 |
MLS002415733 |
F0072 |
(e)-but-2-enedinitrile |
A838708 |
AKOS004902525 |
NCGC00091246-02 |
NCGC00091246-03 |
HMS3039D14 |
cas-764-42-1 |
dtxcid105342 |
tox21_201151 |
NCGC00258703-01 |
dtxsid7025342 , |
17656-09-6 |
c4h2n2 |
(2e)-2-butenedinitrile |
(e)-ch(cn)ch(cn) |
(e)-butenedinitrile |
but-2-enedinitrile, (e)- |
CHEMBL1451833 |
F1905-7136 |
mfcd00001928 |
fumaronitrile, purum, >=98.0% (gc) |
STL185640 |
AMY3223 |
EN300-85123 |
EN300-7399936 |
Excerpt | Reference | Relevance |
---|---|---|
"5 LD50 doses of the nitriles by gavage and they were observed for 12 It for cholinomimetic and central nervous system effects." | ( Effect of dosing vehicle on the toxicity and metabolism of unsaturated aliphatic nitriles. Farooqui, MY; Piper, J; Tamez, A; Ybarra, B, ) | 0.13 |
Excerpt | Relevance | Reference |
---|---|---|
"The effect of dosing vehicle on toxicity and metabolism of unsaturated aliphatic nitriles was investigated in male Sprague-Dawley rats." | ( Effect of dosing vehicle on the toxicity and metabolism of unsaturated aliphatic nitriles. Farooqui, MY; Piper, J; Tamez, A; Ybarra, B, ) | 0.13 |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Luciferase | Photinus pyralis (common eastern firefly) | Potency | 83.4236 | 0.0072 | 15.7588 | 89.3584 | AID1224835 |
interleukin 8 | Homo sapiens (human) | Potency | 66.8242 | 0.0473 | 49.4806 | 74.9780 | AID651758 |
hypoxia-inducible factor 1 alpha subunit | Homo sapiens (human) | Potency | 64.5370 | 3.1890 | 29.8841 | 59.4836 | AID1224846 |
RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 25.4794 | 0.0060 | 38.0041 | 19,952.5996 | AID1159523 |
ATAD5 protein, partial | Homo sapiens (human) | Potency | 6.5104 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
TDP1 protein | Homo sapiens (human) | Potency | 21.1446 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
GLI family zinc finger 3 | Homo sapiens (human) | Potency | 12.7699 | 0.0007 | 14.5928 | 83.7951 | AID1259392 |
AR protein | Homo sapiens (human) | Potency | 56.0164 | 0.0002 | 21.2231 | 8,912.5098 | AID1259247; AID743036; AID743053 |
aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 39.8107 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 35.9906 | 0.0006 | 57.9133 | 22,387.1992 | AID1259377 |
nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 42.7182 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224839; AID1224893 |
progesterone receptor | Homo sapiens (human) | Potency | 45.3094 | 0.0004 | 17.9460 | 75.1148 | AID1346795 |
glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 32.7517 | 0.0002 | 14.3764 | 60.0339 | AID588532; AID720692 |
retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 8.0573 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552 |
retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 19.9090 | 0.0008 | 17.5051 | 59.3239 | AID1159531; AID588544 |
estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 22.8087 | 0.0015 | 30.6073 | 15,848.9004 | AID1259401; AID1259403 |
farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 53.4481 | 0.3758 | 27.4851 | 61.6524 | AID588526; AID743217; AID743220 |
pregnane X nuclear receptor | Homo sapiens (human) | Potency | 64.0013 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 57.3983 | 0.0002 | 29.3054 | 16,493.5996 | AID1259383; AID743075; AID743077; AID743080; AID743091 |
peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 44.6684 | 0.0010 | 24.5048 | 61.6448 | AID588535 |
peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 32.8635 | 0.0010 | 19.4141 | 70.9645 | AID588536; AID588537; AID743140; AID743191 |
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 28.5883 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 57.5187 | 19.7391 | 45.9784 | 64.9432 | AID1159509 |
Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 105.5220 | 0.0391 | 47.5451 | 146.8240 | AID1224896 |
chromobox protein homolog 1 | Homo sapiens (human) | Potency | 89.1251 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 29.7943 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
heat shock protein beta-1 | Homo sapiens (human) | Potency | 64.5370 | 0.0420 | 27.3789 | 61.6448 | AID743210 |
nuclear factor NF-kappa-B p105 subunit isoform 1 | Homo sapiens (human) | Potency | 39.8107 | 4.4668 | 24.8329 | 44.6684 | AID651749 |
nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 46.8985 | 0.0006 | 27.2152 | 1,122.0200 | AID651741; AID720636; AID743202; AID743219 |
nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 13.5161 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
lethal factor (plasmid) | Bacillus anthracis str. A2012 | Potency | 12.5893 | 0.0200 | 10.7869 | 31.6228 | AID912 |
Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 71.3026 | 0.0023 | 19.5956 | 74.0614 | AID651631; AID651743 |
Nuclear receptor ROR-gamma | Homo sapiens (human) | Potency | 23.7101 | 0.0266 | 22.4482 | 66.8242 | AID651802 |
ATPase family AAA domain-containing protein 5 | Homo sapiens (human) | Potency | 60.5212 | 0.0119 | 17.9420 | 71.5630 | AID651632; AID720516 |
Ataxin-2 | Homo sapiens (human) | Potency | 57.0412 | 0.0119 | 12.2221 | 68.7989 | AID651632 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (5.56) | 18.7374 |
1990's | 2 (11.11) | 18.2507 |
2000's | 2 (11.11) | 29.6817 |
2010's | 11 (61.11) | 24.3611 |
2020's | 2 (11.11) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (33.02) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 19 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |